Clinical Trial Update: Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial assessing apatinib combined with radiotherapy in brain metastases from driver-gene negative non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Hubei Cancer Hospital | Conditions: NSCLC | Phase 2 | Status: UNKNOWN